The FDA has granted Fast Track designation to lebrikizumab for the treatment of moderate-to-severe atopic dermatitis.
Participation in 4 therapy seminars resulted in appreciable improvement in pruritus in patients with atopic dermatitis or psoriasis and may be an efficient supplementary method for managing chronic itch in these populations.
Despite well-established associations of psoriasis and atopic dermatitis with depression and suicidality, and recommendations for increased screening in these higher-risk patients, clinical practice gaps remain, with low rates of depression screening.
Skin rather than blood is the primary source for the inflammatory and atherosclerosis/cardiovascular signature, data from this novel study suggests.
Atopic dermatitis is associated with clinically significant mental health symptoms, but nearly half of children with atopic dermatitis and severe mental health impairments may not receive mental healthcare, suggesting a critical practice gap.
PO-SCORAD for black skin is a simple tool that allows patients to easily self-assess atopic dermatitis severity. It may prove a valuable tool for monitoring disease severity between physician visits and involving patients in the management of their disease.
Although the atopic dermatitis treatment patterns found reflect existing clinical guidelines, second-generation antihistamines are not recommended in the management of atopic dermatitis, despite being the third most prescribed medication class.
Data from this analysis indicate that dupilumab induces rapid improvements in AD that can be maintained long term in a significant percentage of Japanese adults with moderate to severe AD, with prolonged benefits in terms of both pruritus and QoL.
The study data showed a 20% increased long-term risk for atrial fibrillation in patients with hospital-diagnosed moderate to severe atopic dermatitis.
Pfizer announced positive topline results from the phase 3 JADE MONO-2 trial of abrocitinib, an oral Janus kinase 1 inhibitor, for the treatment of moderate to severe atopic dermatitis.